Supports heart and overall metabolic health
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide cardiovascular and kidney benefits in non-KT recipients, but evidence in KT recipients remains limited
In clinical trials, the most frequently reported skin-related reactions were mild injection site issues, including redness, itching, or slight swelling
Frequently Asked Questions Can I take ibuprofen if I'm on semaglutide
GLP-1a drugs and their use for weight loss have taken the health care industry by storm, but several issues must be resolved, including how to ensure that those who may benefit most have access while maintaining overall pharmacy benefit affordability, said David Lassen, PharmD, chief clinical officer at Prime
Frontiers in Pharmacology, 16, 1438318